留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析

杨婕,  温华,  马冰,  孙晶

downloadPDF
文章导航 > 药学实践与服务  > 2018 >  36(6): 541-546
杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
引用本文: 杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
shu
YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
Citation: YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
shu

7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析

doi: 10.3969/j.issn.1006-0111.2018.06.014
  • 1.

    中国医科大学附属第一医院呼吸科, 沈阳 110001

  • 2.

    中国医科大学附属第一医院流行病学教研室, 沈阳 110001

  • 3.

    解放军第463医院皮肤科, 沈阳 110042

Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis

  • 1.

    Department of Pneumology, The First Hospital, China Medical University, Shenyang 110001, China

  • 2.

    Department of Epidemiology, The First Hospital, China Medical University, Shenyang 110001, China

  • 3.

    Department of Dermatology, No. 463 Hospital of PLA, Shengyang 110042, China

  • 摘要: 目的 采用网状Meta分析法，比较7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症作用的有效性。 方法 检索CBM、Cochrane Library、Pubmed等数据库，从中提取随机对照试验，进行质量评价。应用软件Stata12.0，采用mvmeta程序包分析数据。 结果 检索相关文献1 091篇，24篇符合标准，共计40 001例患者；按处方药物用量评价预防静脉血栓栓塞症的有效性。直接比较结果：利伐沙班、阿哌沙班优于低分子肝素，结果分别为：RR=0.56，95% CI：0.40~0.78，P<0.05；RR=0.39，95% CI：0.24~0.63，P<0.05。其余5种新型口服抗凝药与低分子肝素比较无显著差别（P>0.05）。间接比较，结果均优于安慰剂。 结论 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的有效性等级排名：阿哌沙班最佳，其次为利伐沙班、依度沙班、Ym150、TAK-442、达比加群酯、贝曲沙班。
    Abstract: Objective To assess the efficacy of seven kinds of new oral anticoagulants in prevention of venous thromboembolism in patients after total hip or knee replacement by a network Meta-analysis. Methods Randomized clinical trials in databases of CBM,Cochrane Library,Pubmed were searched. The quality of the included studies was assessed. Data were analyzed by Stata12.0 software,and mvmeta program package. Results 24 RCTs (in all 1 091 articles,40 001 patients) met the criteria. Prevention for VTE with prescribed dosage was evaluated. Following findings,directly,Rivaroxaban and Apixaban were more effective than low molecular weight heparin,results as (RR=0.56,95%CI:0.40-0.78),P<0.05;(RR=0.39,95%CI:0.24-0.63),P<0.05. The others compared with LMWH,P>0.05,had no statistical significance. Indirectly,these were all superior efficacy to placebo. Conclusion Grade rankings of efficacy for seven kinds of NOACs prevented VTE in patients after THR or TKR,Apixaban was best,followed by Rivaroxaban,Edoxaban,Ym150,TAK-442,dabigatran etexilate,Betrixaban.
  • [1] 吴丹辰,贾镭,徐希奇,等.新型口服抗凝药物预防及治疗静脉血栓栓塞症研究进展[J].中华关节外科杂志[J/OL],2013,7(3):420.
    [2] 邱贵兴.中国骨科大手术静脉血栓栓塞症预防指南[J].中华关节外科杂志[J/OL],2009,3(3):380.
    [3] 张超,陶华,李胜,等.应用Stata软件mvmeta程序包实现网状Meta分析[J].Chin J Evid-based Med,2014,14(9):1150-1159.
    [4] ERIKSSON B,DNHL OE,ROSENEHER N,et al.Dabigatran etexilate for prevention of venous thromboembolism after total hip replacement a randomised double-blin non-inferiority trial[J].Lancet,2007,370(9591):949-956.
    [5] ERIKSSON BI,DAHL OE,HUO MH,et al.Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty[J].Thromb Haemost,2011,105(4):721-729.
    [6] ERIKSSON B,DNHL OE,ROEENCHER N,et al.Oral dabigatran etexilate and subctltalleous enoxparin for the prevention of veneous thromboembolism after total knee replacement the RE-MODEL randomized trial[J].J Thromb Haemost,2007,5(11):2178-2185.
    [7] GINSBERG JS,DAVIDSON BL,COMP PC,et al.Oral thrombin inhibitor or dabigatan etexilate and North Ameriean enoxaparin regimen for prevention of venous thrombomembolism after knee arthroplasty surgery[J].J Arthroplasty,2009,24(1):1-9.
    [8] ERIKSSON BI,BORRIS LC,FRIEDMAN RJ,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty[J].N Engl J Med,2008,358(26):2765-2775.
    [9] KAKKAR AK,BRENNER B,DAHL OE,et al.Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty:a double-blind,randomised controlled trial[J].Lancet,2008,372(9632):31-39.
    [10] LASSEN MR,AGENO W,BORRIS LC,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty[J].N Engl J Med,2008,358(26):2776-2786.
    [11] TURPIE AG,LASSEN MR,DAVIDSON BL,et al.Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4) a randomised trial[J].Lancet,2009,373(9676):1673-1680.
    [12] ERIKSSON BI,BORRIS L,DAHL OE,et al.For the ODIXa-HIP investigators study a randomised trial:a once-daily oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) for thromboprophylaxis after total hip replacement[J]. Circulation,2006,114(22):2374-2381.
    [13] ERIKSSON BI,BORRIS L,DAHL OE,et al.For the ODIXa-HIP investigators study a randomised trial:oral direct factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement[J]. Thromb Haemost,2006,4:121-128.
    [14] TURPIE, FISHER, BAUER,et al.BAY 59-7939 an oral direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement a phase Ⅱ dose-ranging study[J].Thromb Haemost,2005,3(11):2479-2486.
    [15] ERIKSSON BI,BORRIS LC,DAHL OE,et al.Dose-escalation study of rivaroxaban(BAY 59-7939) an oral direct factor Xa inhibitor-for the prevention of venous thromboembolism in patients undergoing total hip replacement[J].Thromb Res,2007,120(5):685-693.
    [16] LASSEN MR,DAVIDSON BL,GALLUS A,et al.The efficacy and safety of apixaban an oral direct factor Xa inhibitor as thromboprophylaxis in patients following total knee replacement[J].J Thromb Haemost,2007,5(12):2368-2375.
    [17] LASSEN MR,RASKOB GE,GALLUS A,et al.Apixaban or enoxaparin for thromboprophylaxis after knee replacement[J].N Engl J Med,2009,361(6):594-604.
    [18] LASSEN MR,RASKOB GE,GALLUS A,et al.Apixaban versus enoxaparin for thromboprophylaxis after knee replacement a randomised double-blind trial[J].Lancet,2010,375(9717):807-815.
    [19] LASSEN MR,GALLUS A,RASKOB GE,et al.Apixaban versus enoxaparin for thromboprophylaxis after hip replacement[J].N Engl J Med,2010,363(26):2487-2498.
    [20] FUJI T,FUJITA S,TACHIBANA S,et al.A dose-ranging study evaluating the oral factor Ⅹa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty[J].J Thromb Haemost,2010,8(11):2458-2468.
    [21] FUJI T,FUJITA S,KAWAI Y,et al.Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty:STARS J-V[J].Thromb J,2015,13:27.
    [22] RASKOB G,COHEN AT,ERIKSSON BI,et al.Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement.a randomised double-blind dose-response study[J].Thromb Haemost,2010,104(3):642-649.
    [23] TURPIE AG,BAUER KA,DAVIDSON BL,et al. A randomized evaluation of betrixaban an oral factor Xa inhibitor for prevention of thromboembolic events after total knee replacement[J].Thromb Haemost,2009,101(1):68-76.
    [24] WEITZ JI,CAO C,ERIKSSON BI,et al.A dose-finding study with TAK-442 an oral factor Xa inhibitor in patients undergoing elective total knee replacement surgery[J].Thromb Haemost,2010,104(6):1150-1157.
    [25] ERIKSSON BI,TURPIE AG,LASSEN MR,et al.Prevention of venous thromboembolism with an oral factor Xa inhibitor YM150 after total hip arthroplasty a dose finding study (ONYX-2)[J].Journal of Thrombosis and Haemostasis,2010,8:714-721.
    [26] FUJI T,NAKAMURA M,TAKEUCHI M.Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery results from 2 randomized placebo-controlled,double-blind studies[J].Clinical and Applied Thrombosis Hemostasis,2014,20(2):199-211.
    [27] ERIKSSON BI,AGNELLI G,GALLUS AS,et al.Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty a randomised phase Ⅱb dose confirmation study (ONYX-3)[J].Thromb Haemost,2014,111(2):213-225.
    [28] STEVENSON M,SCOPE A,HOLMES M,et al.Rivaroxaban for the prevention of venous thromboembolism a single technology appraisal[J].Health Technol Assess,2009,13:43-48.
    [29] GOMEZ-OUTESA,TERLEIRA-FERNANDEZ AI,SUAREZ-GEA ML,et al.Dabigatran rivaroxaban or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement systematic review meta-analysis,and indirect treatment comparisons[J].BMJ,2012,344(14):3675.
  • [1] 黄韵, 张正银, 金英, 郑怡菁, 李铁军, 孙莉莉.  耐碳青霉烯类肺炎克雷伯菌及大肠埃希菌临床分离株耐药性及耐药基因分析 . 药学实践与服务, 2024, 42(10): 439-444. doi: 10.12206/j.issn.2097-2024.202309059
    [2] 史生辉, 石飞, 雷琼, 王亚峰, 吴雪花.  青藏高原肺结核合并念珠菌感染患者的病原菌分布特点及耐药率分析 . 药学实践与服务, 2024, 42(6): 260-262, 272. doi: 10.12206/j.issn.2097-2024.202304014
    [3] 戴菲菲, 傅翔, 陈琼年, 俞苏纯.  上海某二级医院革兰阴性菌流行特征的回顾性分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202305005
    [4] 刘依秦, 王超群, 邱娇娜.  胆宁片预处理在糖尿病患者结肠镜检查前的应用效果分析 . 药学实践与服务, 2024, 42(9): 407-410. doi: 10.12206/j.issn.2097-2024.202407037
    [5] 瞿文君, 白若楠, 崔力, 周琰.  基于联合库存的公立医院多院区药品采购模式分析 . 药学实践与服务, 2024, 42(7): 315-318. doi: 10.12206/j.issn.2097-2024.202401002
    [6] 宋红卫, 王燕, 方铭, 马云鹏, 钟超, 徐一新, 徐峰, 周婷.  2021−2023年我院药品不良反应的特点分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202404041
    [7] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [8] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
    [9] 尹小娟, 台力丽, 肖俊峰, 季波.  铜绿假单胞菌合并按蚊伊丽莎白菌肺部感染的病例分析 . 药学实践与服务, 2024, 42(5): 223-226. doi: 10.12206/j.issn.2097-2024.202310042
    [10] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 291-296. doi: 10.12206/j.issn.2097-2024.202312054
    [11] 陈怡君, 王卓, 何苗, 张宇, 田泾.  泌尿系统碎石术抗菌药物预防使用合理管控实践 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402034
    [12] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
    [13] 姚瑞阳, 于海征, 李耀盺, 张磊.  丹参FBXL 基因家族的鉴定和表达模式分析 . 药学实践与服务, 2024, 42(11): 461-470. doi: 10.12206/j.issn.2097-2024.202407034
    [14] 张岩, 李炎君, 刘家荟, 邓娇, 原苑, 张敬一.  药物性肝损伤不良反应分析 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404034
    [15] 郭灵怡, 刘艳超, 高路, 刘瑞瑶, 吕权真, 俞媛.  醋酸卡泊芬净单硬脂酸甘油酯纳米粒抗白色念珠菌感染的增效作用研究 . 药学实践与服务, 2024, 42(): 1-8. doi: 10.12206/j.issn.2097-2024.202310043
    [16] 陈炳辰, 佟达丰, 万苗, 闫飞虎, 姚建忠.  UPLC-MS/MS法测定小鼠血浆中紫杉醇脂肪酸酯前药及其药代动力学研究 . 药学实践与服务, 2024, 42(8): 341-345. doi: 10.12206/j.issn.2097-2024.202404082
    [17] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 319-324. doi: 10.12206/j.issn.2097-2024.202308062
    [18] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(10): 451-456. doi: 10.12206/j.issn.2097-2024.202310044
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3413
  • HTML全文浏览量:  482
  • PDF下载量:  423
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-12-01
  • 修回日期:  2018-08-25

7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析

doi: 10.3969/j.issn.1006-0111.2018.06.014
  • 1. 中国医科大学附属第一医院呼吸科, 沈阳 110001
  • 2. 中国医科大学附属第一医院流行病学教研室, 沈阳 110001
  • 3. 解放军第463医院皮肤科, 沈阳 110042
  • 收稿日期: 2017-12-01
  • 修回日期: 2018-08-25

摘要: 目的 采用网状Meta分析法，比较7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症作用的有效性。 方法 检索CBM、Cochrane Library、Pubmed等数据库，从中提取随机对照试验，进行质量评价。应用软件Stata12.0，采用mvmeta程序包分析数据。 结果 检索相关文献1 091篇，24篇符合标准，共计40 001例患者；按处方药物用量评价预防静脉血栓栓塞症的有效性。直接比较结果：利伐沙班、阿哌沙班优于低分子肝素，结果分别为：RR=0.56，95% CI：0.40~0.78，P<0.05；RR=0.39，95% CI：0.24~0.63，P<0.05。其余5种新型口服抗凝药与低分子肝素比较无显著差别（P>0.05）。间接比较，结果均优于安慰剂。 结论 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的有效性等级排名：阿哌沙班最佳，其次为利伐沙班、依度沙班、Ym150、TAK-442、达比加群酯、贝曲沙班。

English Abstract

杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
引用本文: 杨婕, 温华, 马冰, 孙晶. 7种新型口服抗凝药预防全髋、膝关节置换术后静脉血栓栓塞症的网状Meta分析[J]. 药学实践与服务, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
shu
YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
Citation: YANG Jie, WEN Hua, MA Bing, SUN Jing. Seven kinds of new oral anticoagulants for prevention of venous thromboembolism after total hip or knee arthroplasty: a net Meta-analysis[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(6): 541-546. doi: 10.3969/j.issn.1006-0111.2018.06.014
shu

    全文HTML

参考文献 (29)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计